Targeting thioredoxin reductase 1 by Andrographolide contributes to inducing ROS-mediated apoptosis in human NSCLC...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality, necessitating novel therapeutic agents.
• Andrographolide (Andro), a natural compound, demonstrates anticancer potential across various cancer types.
• Understanding the precise mechanisms of Andro's action in NSCLC is crucial for its clinical application.

Purpose of the Study:

• To elucidate the molecular mechanisms by which Andrographolide (Andro) exerts its antitumor effects in non-small cell lung cancer (NSCLC).
• To investigate the role of thioredoxin reductase 1 (TrxR1) in mediating Andro's cytotoxicity and therapeutic efficacy in NSCLC.
• To evaluate Andro as a potential therapeutic agent and TrxR1 as a drug target for NSCLC.

Main Methods:

• Investigated Andro's effects on human NSCLC cells, focusing on reactive oxygen species (ROS) generation, endoplasmic reticulum (ER) stress, and apoptosis.
• Utilized gene knockdown and overexpression techniques to assess the role of TrxR1 in Andro's mechanism of action.
• Evaluated Andro's efficacy in a mouse model of NSCLC xenografts.
• Analyzed clinical data correlating TrxR1 expression levels with patient prognosis.

Main Results:

• Andro inhibits TrxR1, leading to increased ROS production, ER stress, and apoptosis in NSCLC cells.
• ROS generation is essential for Andro-induced ER stress and apoptosis, as blocking ROS reversed these effects.
• TrxR1 knockdown enhanced Andro sensitivity, while TrxR1 overexpression conferred resistance.
• Andro treatment suppressed tumor growth in vivo, correlating with TrxR1 inhibition and ROS accumulation.
• Elevated TrxR1 expression in NSCLC patients is linked to poorer prognosis.

Conclusions:

• Andrographolide (Andro) exerts its antitumor effects in NSCLC by targeting and inhibiting TrxR1, inducing ROS-dependent ER stress and apoptosis.
• TrxR1 plays a critical role in regulating cellular response to Andro treatment.
• TrxR1 inhibition represents a viable therapeutic strategy for NSCLC, with Andro as a potential drug candidate.